Sulforaphane in Clinical Medicine: A Decade of Research Progress and Therapeutic Potential

MedXY Editorial Team•Oct 4, 2025•Cardiology

Sulforaphane (SFN), a natural isothiocyanate mainly derived from cruciferous vegetables, activates the Nrf2 pathway to mediate antioxidant, anti-inflammatory, and cytoprotective effects.
Recent randomized controlled trials (RCTs) have demonstrated SFN’s safety and pharmacokinetic profiles in humans, with varied efficacy signals reported in neurological, metabolic, psychiatric, and cardiovascular conditions.
Systematic reviews and meta-analyses of preclinical models affirm SFN’s renoprotective and lipid-modulating properties, encouraging further clinical investigations in chronic kidney disease and metabolic syndrome.
Emerging evidence suggests potential clinical utility of SFN in autism spectrum disorder (ASD), depression related to cardiac intervention, non-alcoholic fatty liver disease (NAFLD), and certain cancers, although larger, well-powered trials remain necessary.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Sulforaphane (SFN), a natural isothiocyanate mainly derived from cruciferous vegetables, activates the Nrf2 pathway to mediate antioxidant, anti-inflammatory, and cytoprotective effects.
Recent randomized controlled trials (RCTs) have demonstrated SFN’s safety and pharmacokinetic profiles in humans, with varied efficacy signals reported in neurological, metabolic, psychiatric, and cardiovascular conditions.
Systematic reviews and meta-analyses of preclinical models affirm SFN’s renoprotective and lipid-modulating properties, encouraging further clinical investigations in chronic kidney disease and metabolic syndrome.
Emerging evidence suggests potential clinical utility of SFN in autism spectrum disorder (ASD), depression related to cardiac intervention, non-alcoholic fatty liver disease (NAFLD), and certain cancers, although larger, well-powered trials remain necessary.